Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MR13A9 in Hemodialysis Patients With Pruritus
NCT04711603Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of difelikefalin in uremic pruritus, sponsored by Kissei Pharmaceutical Co., Ltd.. Started Jan 2021; status: completed.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT04711603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711603.